Regulatory News In Brief
Diagnostics oversight report finalized: In a final 1report released April 30, an HHS advisory committee recommends that FDA "address" all diagnostic tests, genetic or otherwise, using a risk-based framework to determine the appropriate level of regulatory oversight. Diagnostics are currently subject to various levels of oversight from FDA, CMS's 1988 Clinical Laboratory Improvement Amendments (CLIA) and state agencies. FDA, CMS and other agency oversight procedures should be harmonized, the report says. In March 2007, HHS Secretary Michael Leavitt asked the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) to draft a genetic test oversight report; the draft was released last November. The final report reflects discussions held this February on how best to expand test oversight and health education to address significant gaps that put the public at risk (2"The Gray Sheet" Feb. 25, 2008, p. 14). Lab groups, however, are wary that expanded FDA oversight over all lab-developed tests could lead to redundancies between FDA and CLIA requirements and stifle innovation
More from Archive
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.
St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.
Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.
More from Medtech Insight
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
- • By
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.





